TG Therapeutics (TGTX) Announces $60M in ATM Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility
May 6, 2020 7:01 AM EDTNEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it has raised gross proceeds of approximately $60 million through its At-the-Market (ATM) facility, $40 million of which came from longtime shareholder, RA Capital Management. The Company sold approximately 3.5 million shares of the Companys common stock on May 5, 2020, at the then-prevailing market prices.Â
TG Therapeutics intends to use the capital raised through the ATM to fund the ongoing development and commercialization of the Companys lead assets, ublituximab and umbralisib, as well as for research and development activities of the Companys... More
